Literature DB >> 4276758

Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.

W Sadée, U Abshagen, C Finn, N Rietbrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4276758     DOI： 10.1007/bf00499190

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  14 in total

1.  [ON THE METABOLISM OF 3-(3-OXO-7-ALPHA-ACETYLTHIO-17-BETA-HYDROXY-4-ANDROSTEN-17-ALPHA-YL)-PROPIONIC ACID-GAMMA-LACTONE].

Authors:  E GERHARDS; R ENGELHARDT
Journal:  Arzneimittelforschung       Date:  1963-11

2.  PHARMACOLOGICAL PROPERTIES OF A MINERALOCORTICOID ANTAGONIST (SC-14266).

Authors:  C M KAGAWA; D J BOUSKA; M L ANDERSON; W F KROL
Journal:  Arch Int Pharmacodyn Ther       Date:  1964-05-01

3.  [TUBULAR EFFECTS AND RENAL ELIMINATION OF SPIROLACTONES].

Authors:  G HOLLMANN; G SENFT; C WERNER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-06-11

4.  Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone.

Authors:  C M KAGAWA
Journal:  Endocrinology       Date:  1960-07       Impact factor: 4.736

5.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

6.  Cerebral uptake of a 3 H-labelled spirolactone compound in the dog.

Authors:  P Schmiedek; W Sadée; A Baethmann
Journal:  Eur J Pharmacol       Date:  1973-02       Impact factor: 4.432

7.  [Studies on organ- and subcellular distribution of 3 H-spironolactone in animals].

Authors:  D Platt; H Pauli
Journal:  Arzneimittelforschung       Date:  1972-10

8.  Fluorometric microassay for spironolactone and its metabolites in biological fluids.

Authors:  W Sadée; M Dagcioglu; S Riegelman
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

9.  Disposition of tritium-labeled spirolactones in the dog.

Authors:  W Sadée; S Riegelman; S C Jones
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

10.  Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).

Authors:  A Karim; E A Brown
Journal:  Steroids       Date:  1972-07       Impact factor: 2.668
View more
  9 in total

1.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

2.  Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.

Authors:  U Abshagen; H Rennekamp; J Kuhlmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

3.  Effect of entekohepatic circulation on the pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; U von Grodzicki; U Hirschberger; H Rennekamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

4.  Pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

5.  Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Authors:  C S Cook; C L Hauswald; G L Schoenhard; C E Piper; A Patel; F M Radzialowski; J D Hribar; W Aksamit; P Finnegan; R H Bible
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

6.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

7.  Metabolism of digitoxin in man and its modification by spironolactone.

Authors:  K E Wirth; J C Frölich; J W Hollifield; F C Falkner; B S Sweetman; J A Oates
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

8.  Non-interaction of spironolactone medication and cortisol metabolism in man.

Authors:  U Abshagen; S Spörl; M L'age
Journal:  Klin Wochenschr       Date:  1978-02-01

9.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.